Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2025
0mins
Source: Benzinga
MongoDB Financial Results: MongoDB, Inc. shares surged 16.6% in pre-market trading after reporting better-than-expected first-quarter results for fiscal 2026 and raising its revenue outlook to between $2.25 billion and $2.29 billion.
Market Movements: Several stocks experienced significant pre-market trading fluctuations, with notable gainers including MKDWELL Tech Inc. (up 232%) and Ctrl Group Limited (up 99.9%), while Helius Medical Technologies, Inc. saw a sharp decline of 80.1%.
Analyst Views on KAPA
Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.890
Low
4.00
Averages
8.00
High
12.00
Current: 0.890
Low
4.00
Averages
8.00
High
12.00
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
